FDA issued guidance to firms interested in participating in a program involving the submission of CMC information containing emerging technology. The program is open to companies that intend to include the technology as part of a regulatory submission to CDER, including INDs, NDAs, ANDAs, BLAs, and DMFs.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
